Physician profile
Prasuna Jami
NPI 1043318132
$11,476.55
in general payments reported to CMS, 2019-2025
46 companies · $2,613 in 2025
The $2,613 reported for 2025 was more than what 81% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $459 · 2020: $162 · 2021: $349 · 2022: $2,568 · 2023: $2,810 · 2024: $2,516 · 2025: $2,613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,939.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,938.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,511.64 | 2021-2025 | Ozempic, Rybelsus, Sogroya |
| Insulet Corporation | $941.90 | 2020-2025 | Omnipod |
| Lilly USA, LLC | $860.23 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $805.15 | 2019-2025 | Evenity, Prolia, Tepezza |
| Sanofi-Aventis U.S. LLC | $800.61 | 2019-2025 | |
| Mannkind Corporation | $793.53 | 2022-2024 | Afrezza |
| Abbott Laboratories | $551.75 | 2019-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $514.19 | 2019-2025 | Jardiance |
| Dexcom, INC. | $454.89 | 2022-2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $445.52 | 2022-2025 | Minimed 780g, Intellis Adaptivestim |
| Astrazeneca Pharmaceuticals LP | $378.09 | 2019-2023 | Farxiga |
| Tandem Diabetes Care, INC. | $327.46 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Corcept Therapeutics | $292.69 | 2019-2024 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $289.32 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $279.21 | 2022-2025 | Gvoke Hypopen |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $273.28 | 2022-2025 | |
| Amneal Pharmaceuticals LLC | $217.80 | 2021-2025 | Unithroid |
| Alexion Pharmaceuticals, INC. | $203.14 | 2019-2025 | Strensiq |
| Ascendis Pharma Endocrinology INC | $172.47 | 2024-2025 | Yorvipath |
| Cequr Corporation | $169.62 | 2024-2025 | Cequr Simplicity |
| Amarin Pharma, INC. | $132.47 | 2019-2021 | |
| Abbvie INC. | $101.87 | 2022-2023 | |
| Sequel Med Tech, LLC | $85.40 | 2025 | Twiist |
| Ibsa Pharma INC. | $83.26 | 2023-2025 | Tirosint, Licart, Tirosint |
| Horizon Therapeutics Plc | $81.67 | 2023 | Tepezza |
| Recordati_rare_diseases_inc. | $78.09 | 2023-2025 | Isturisa, Signifor Lar |
| Madrigal Pharmaceuticals | $69.64 | 2025 | Rezdiffra |
| Astellas Pharma US INC | $65.27 | 2023-2025 | Veozah |
| Kyowa Kirin, INC. | $60.24 | 2023-2024 | Crysvita |
| Ascensia Diabetes Care US INC. | $58.20 | 2023 | |
| Beta Bionics, INC. | $50.64 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Grt US Holding, INC. | $40.87 | 2022 | |
| Nevro Corp. | $39.53 | 2021 | |
| Rhythm Pharmaceuticals, INC. | $29.55 | 2025 | Imcivree |
| Neurocrine Biosciences, INC. | $29.48 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $21.60 | 2021 | |
| Lifescan, INC. | $21.08 | 2022 | |
| Soleno Therapeutics, INC. | $20.53 | 2025 | Vykat Xr |
| Aimmune Therapeutics, INC. | $20.03 | 2024 | |
| Janssen Pharmaceuticals, INC | $18.73 | 2019 | |
| Esperion Therapeutics, INC. | $16.73 | 2020 | |
| Vivus LLC | $15.08 | 2023 | Qsymia |
| Medtronic Minimed, INC. | $13.98 | 2019 | |
| Acella Pharmaceuticals, LLC | $13.97 | 2025 | NP Thyroid 60 |
| Kowa Pharmaceuticals America, INC. | $13.79 | 2021 | |
| Endo Pharmaceuticals INC. | $12.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prasuna Jami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.